Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
MapLight Therapeutics reported Q3 2026 financial results and provided a clinical pipeline update, including plans for its Phase 3 ZEPHYR-2 trial in schizophrenia. The company ended the quarter with $463.4 million in cash, which is expected to fund operations through 2028 and key clinical readouts.
Term
Q3 2026
“Following the positive results from our ZEPHYR study, we are focused on advancing ML-007C-MA into an additional registrational study and positioning it to compete in the broader antipsychotic market.”
Chris Kroeger, Co-Founder and Chief Executive Officer
“We believe that the strength and consistency of the ZEPHYR efficacy results, combined with the ease-of-use tolerability profile, provide a solid foundation for our planned Phase 3 trial and reinforce our confidence in the potential of ML-007C-MA in schizophrenia.”
Chris Kroeger, Co-Founder and Chief Executive Officer
Xtend AI Robotics reported Q3 2026 revenue of $14.9 million, a 281% year-over-year increase, driven by its AI Robotics segment. The company ended the quarter with a fully funded backlog exceeding $100 million and $66.7 million in cash following its NYSE listing and business combination with JFB Construction.
Term
Q3 2026
“Our first quarter as a public company shows our strategy is working. Revenue nearly quadrupled, nine-month revenue has already passed all of 2025, and we ended the quarter with a fully funded backlog of more than $100 million. XTEND is not just another drone company. We are a Physical AI company”
Aviv Shapira, Co-Founder and Chief Executive Officer
Larimar Therapeutics reported third quarter 2026 financial results and announced the completion of its rolling BLA submission to the FDA for nomlabofusp in Friedreich’s ataxia. The company ended the quarter with $128.7 million in cash, providing a projected runway into late Q2 2027 as it prepares for a potential U.S. launch in Q3 2027.
“Completing the BLA submission for nomlabofusp marks a major milestone for Larimar and the Friedreich’s ataxia (FA) community. The next 12 months are expected to bring several pivotal registrational catalysts, including FDA review of our application and progression of FORWARD-FA, our global confirmatory Phase 3 study.”
Carole Ben-Maimon, M.D., Chief Executive Officer
“In parallel, we are preparing for a potential U.S. launch in the third quarter of 2027, if approved, while evaluating options to support global commercialization.”
Instil Bio, Inc. reported a net loss of $13.0 million for the nine months ended September 30, 2026, a significant reduction from the $63.5 million loss in the prior year period. The company is transitioning its strategy, having discontinued its lead product candidate AXN-2510 in January 2026, and is currently seeking to in-license or acquire new therapeutic candidates.
Amdocs Director La Vega Rafael De Buys $102K of Stock
La Vega Rafael De, Director, bought 2,297 shares of Amdocs Ltd at $44.51 a share, worth $102K in total on Nov 12, 2026. Shares held after the trade: 38,191 (+6.4%).
Sativus Tech Corp. reported a net loss of $539 thousand for the nine months ended September 30, 2026, compared to $923 thousand in the prior year. The company faces substantial doubt about its ability to continue as a going concern due to an accumulated deficit of $24.9 million and negative operating cash flows.
Venu Holding Corp reported total revenues of $14.09 million for the nine months ended September 30, 2026, a slight increase from $13.37 million in the prior year. The company experienced a significant net loss of $49.81 million during this period, driven by high general and administrative expenses and equity-based compensation. Total assets grew to $587.63 million, primarily due to a substantial increase in property and equipment related to amphitheater development.
Xtant Medical Holdings reported total assets of $75.2 million as of September 30, 2026, a decrease from $94.1 million at year-end 2025, primarily driven by a reduction in cash and the settlement of a $10.5 million note receivable. The company is currently undergoing a strategic review by its Board of Directors and recently expanded its product portfolio with the exclusive distribution of HEMOBLAST Bellows.
QVC Group, Inc. has emerged from Chapter 11 bankruptcy proceedings as of July 20, 2026, implementing a reorganization plan that includes approximately $1.3 billion in Takeback Debt and a $600 million Exit ABL Facility. The company reported 49,999,897 shares of common stock outstanding as of October 31, 2026, and is now operating under fresh start accounting which limits comparability to historical financial periods.
Barrel Energy Inc. reported a significant net loss of $1,518,216 for the nine months ended September 30, 2026, compared to a net income of $53,795 in the prior year period. The loss was primarily driven by a $1,056,653 change in the fair value of derivative liabilities and a substantial increase in operating expenses including consulting, marketing, and R&D.
Nixxy, Inc. reported a net loss of $3.88 million for the nine months ended September 30, 2026, an improvement from the $11.00 million loss in the prior year period. Revenue grew significantly to $74.51 million for the nine months, though the company continues to operate with a working capital deficit and an accumulated deficit of $117.68 million.
Invivyd, Inc. reported a significant increase in net loss to $119.3 million for the nine months ended September 30, 2026, compared to $41.4 million in the prior year, driven by a surge in R&D and SG&A expenses. Despite the higher loss, total revenue grew to $43.5 million from $36.2 million year-over-year, while cash and cash equivalents decreased to $126.4 million.
Prelude Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $142.7 million which is expected to fund operations into Q2 2028. The company advanced its clinical pipeline with the initiation of a Phase 1 study for PRT13722 in breast cancer and entered a clinical collaboration with Eli Lilly to evaluate combination therapies.
“The first three quarters of 2026 have been a period of strong execution for Prelude. We rapidly advanced two potential first-in-class programs into clinical development including PRT12396, a mutant-selective JAK2V617F inhibitor with disease-modifying potential in myeloproliferative neoplasms (MPNs) and PRT13722, a selective KAT6A degrader with the potential to improve the safety and efficacy of KAT6 inhibition, a clinically validated approach in HR+ breast cancer.”
Kris Vaddi, Ph.D., Chief Executive Officer of Prelude
Invivyd reported Q3 2026 financial results, highlighted by $15.4 million in PEMGARDA net product revenue, representing 18% year-over-year growth. The company also announced that Phase 3 clinical trial data for VYD2311 is expected imminently following regulatory dialogue with the FDA regarding accelerated approval pathways.
Term
Q3 2026
“We are excited about the progress made to advance VYD2311 to meet the urgent need for new options to prevent Americans from getting sick from COVID and suffering from the debilitating impact of Long COVID or COVID vaccine injury.”
Marc Elia, Chairman and Chief Executive Officer
“PEMGARDA’s continued growth, even in the face of declining COVID vaccine utilization and announcement of the termination of its Emergency Use Authorization in mid-2027, demonstrates clear demand for monoclonal antibodies.”
ExlService Holdings Chairman & CEO Rohit Kapoor Sells $4.32M of Stock
Rohit Kapoor, Chairman & CEO, sold 100,000 shares of ExlService Holdings, Inc. at $43.24 a share, worth $4.32M in total on Nov 12, 2026. Shares held after the trade: 565,925 (-15.0%).
Lexeo Therapeutics reported total assets of $243.9 million as of September 30, 2026, a decrease from $268.7 million at year-end 2025. The company maintains a strong liquidity position with $90.2 million in cash and cash equivalents and $104.6 million in current U.S. Treasury securities to fund its ongoing clinical development of LX2006 and LX2020.
InspireMD, Inc. priced an underwritten public offering of common stock and pre-funded warrants for gross proceeds of approximately $37.5 million. The offering includes 7,342,308 shares of common stock and pre-funded warrants for 50,350,000 shares, each accompanied by Series L warrants. Proceeds are intended for research and development, sales and marketing, and general corporate purposes.
AirJoule Technologies reported Q3 2026 results, highlighting the completion of its BitSink acquisition and the delivery of its first AirJoule Prime system to a Data4 data center in France. The company also appointed Timothy N. White, an executive from Carrier Global Corporation, to its board of directors.
Term
Q3 2026
“This quarter marks an important step in AirJoule Technologies’ evolution. We expanded our commercial capabilities through the acquisition of BitSink, strengthened our market access through partnerships like Kubota, and sharpened our AirJoule product roadmap around our two highest-value platforms: Prime for water generation and Core DH for dehumidification.”
Matt Jore, Founder and Chief Executive Officer
“BitSink’s $15 million in signed purchase orders provides greater near-term revenue visibility, while our AirJoule products are moving through a more defined path to commercialization. We are deploying systems in customer environments, measuring real-world performance, and working to validate the economics that will support broader adoption.”
Xtant Medical reported Q3 2026 revenue of $24.3 million, a decrease from $33.3 million in the prior year primarily due to divested businesses and the absence of wound care licensing revenue. The company's Board of Directors also announced a formal strategic review process to evaluate operational improvements, capital structure alternatives, and potential business combinations or transactions.
Term
Q3 2026
“The Board is disappointed with Xtant’s financial performance this quarter, which marks the second consecutive quarter in which our results have not met our guidance. That is unacceptable.”
Stavros Vizirgianakis, Chairman of the Board
“The Board’s priorities are clear: improve execution, improve financial performance, and maximize stockholder value through the strategic review process.”
Cypherpunk Technologies reported its Q3 2026 financial results, highlighted by the launch of its Zcash mining operations which generated $9.9 million in revenue from 8,967.29 ZEC mined. The company expanded its treasury to 341,858.75 ZEC, representing approximately 2.01% of the circulating supply, following its acquisition of a mining fleet from Moria Mining.
Term
Q3 2026
“The launch of Cypherpunk Mining in August was transformative, as it enabled the production of ZEC alongside our purchases and contributes to the security of the Zcash network. In the first six weeks of operation, our fleet earned 8,967.29 ZEC as a result of an exceptional 95% uptime, all of which was added to our treasury in a momentous third quarter for the company.”
Douglas E. Onsi, President and Chief Executive Officer
“The quarter marked a major milestone for Cypherpunk, and we are already planning for significant continued growth. We intend to increase our overall hashrate through additional equipment purchases with the goal of representing approximately 25% of the total Zcash network over time.”
Lexeo Therapeutics announced positive interim Phase I/II data for LX2020 in PKP2-associated arrhythmogenic cardiomyopathy, showing an 80% mean reduction in non-sustained ventricular tachycardia (NSVT) in high-dose cohorts. The company also reported that the FDA is open to using NSVT as a primary surrogate endpoint to support potential accelerated approval in a planned pivotal study.
“The magnitude and consistency of NSVT reduction far exceed what available therapies have historically achieved, underscoring how LX2020 could meaningfully improve outcomes for individuals with PKP2-ACM.”
R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics
InMed Pharmaceuticals M&A Deal with Mentari Therapeutics, Inc.
InMed Pharmaceuticals Inc. (now renamed Mentari Therapeutics, Inc.) completed its previously announced business combination with private Delaware corporation Mentari Therapeutics on November 6, 2026. This filing provides the required historical financial statements and management's discussion for the acquired Mentari entity for the period ended September 30, 2026. The combined company now trades on Nasdaq under the ticker 'MTRI'.
Xtend AI Robotics, Inc. filed its 10-Q for the quarter ended September 30, 2026, following its recent merger with JFB Construction Holdings. The company reports a history of operating losses and limited revenue, focusing on the integration of its AI-driven robotics software across third-party unmanned platforms.
DUKE Robotics Corp. reported revenues of $448 thousand for the nine months ended September 30, 2026, with a net loss of $2.46 million. The company significantly strengthened its cash position to $6.4 million following a common stock offering that raised $7.26 million in net proceeds.
Elauwit Connection reported Q3 2026 financial results featuring a 104% sequential revenue increase to $5.6 million, driven by a ramp in construction activity. Key growth indicators showed strength as billed units rose 140% year-over-year and monthly recurring revenue (MRR) grew 66% to $539,000.
Bruker Corporation has appointed Dr. Eicke Latz to its Board of Directors, effective January 1, 2027, expanding the board to twelve members. Dr. Latz is a physician-scientist and biopharma entrepreneur who currently serves as the Scientific Director of the German Rheumatology Research Center. Additionally, the Board declared a quarterly cash dividend of $0.05 per share payable on January 7, 2027.
Instil Bio reported third quarter 2026 financial results, highlighting a cash position of $67.1 million which is expected to fund operations through 2027. The company is transitioning to an asset-focused development model through subsidiaries while reporting a significantly narrowed net loss compared to the prior year period.
Minerva Neurosciences hosted a Key Opinion Leader (KOL) event and filed an updated investor presentation regarding roluperidone, its product candidate for schizophrenia. The filing includes a revised transcript of the event to clarify that regulatory counsel's expressions of confidence regarding FDA approval were personal opinions and not assurances of future regulatory decisions.
StandardAero entered into an accelerated share repurchase (ASR) agreement with Morgan Stanley to buy back $350 million of its common stock. To fund the transaction and other corporate purposes, the company also secured a $600 million incremental senior secured term loan B facility. The buyback is part of a larger $1.0 billion share repurchase program authorized by the board.
Hornbeck Offshore Services President & CEO Todd M. Hornbeck Buys $500K of Stock
Todd M. Hornbeck, President & CEO, bought 85,912 shares of Hornbeck Offshore Services, Inc. at $5.82 a share, worth $500K in total on Nov 13, 2026. Shares held after the trade: 6,036,426 (+1.4%).